Lonza cuts 125 jobs as it moves cell work from U.S. plant hit with warning letter

7 years ago

by David Miller

979 Views

Written by David Miller

The decision by Swiss drugmaker Lonza to move cell-therapy work out of a U.S. facility that was hit by an FDA warning letter last year will cost the plant about 125 jobs.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller

Don`t Leave Yet!